The latest generation of ProFound AI for 2D Mammography outperforms the previous product version, offering standalone performance improvements of up to 4% increased sensitivity, up to 10% improved specificity and up to 40% faster processing. “By using this leading-edge technology, both general and breast radiologists can potentially improve their accuracy and performance, which may in turn have a positive impact on women and the healthcare system overall.” “The European launch of our third generation of ProFound AI for 2D Mammography demonstrates iCAD’s steadfast commitment to improving breast cancer detection for all women worldwide,” said Stacey Stevens, President of iCAD, Inc. In addition, the Company will showcase its most recent technological advancements, including the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT) and ProFound AI® Risk, in its booth (#226A). (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will unveil the latest generation of ProFound AI® for 2D Mammography at the Journées Francophones de Radiologie (JFR) meeting in Paris, Oct. Latest generation of ProFound AI Risk, now available for digital breast tomosynthesis, provides an accurate, short-term breast cancer risk estimation for women, based only on a screening mammogram Many of these cancers are diagnosed as interval breast cancers, defined as those that emerge after a normal mammogram but before the woman's next scheduled screening.Leading-edge AI solution for 2D mammography enhances cancer detection performance for clinicians, with improved sensitivity, specificity, and processing times over previous versions Regular, age-based mammography screening reduces breast cancer mortality by approximately 20%, but screening mammography can still miss 20 to 40% of breast cancers. This solution, now available for tomosynthesis, provides an accurate estimate of the risk of short-term breast cancer, which is truly personalized for each woman. In addition, the new version of ProFound AI Risk will also be available for demonstration at the iCAD booth at JFR. "By using this leading-edge technology, both general and breast radiologists can potentially improve their accuracy and performance, which may in turn have a positive impact on women and the healthcare system overall." "The European launch of our third generation of ProFound AI for 2D Mammography demonstrates iCAD's steadfast commitment to improving breast cancer detection for all women worldwide," said President Stacey Stevens. In addition, the company, based in Nashua, New Hampshire, will showcase its most recent technological advancements, including the latest generations of ProFound AI® for Digital Breast Tomosynthesis (DBT) and ProFound AI® Risk, in its booth. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will unveil the latest generation of ProFound AI® for 2D Mammography at the Journées Francophones de Radiologie (JFR) meeting in Paris, Friday through Monday. ICAD to Take Wraps off Next Generation AI